MediWound announces $30M registered direct offering

Core Points - MediWound has entered into a definitive securities purchase agreement for the sale of 1,734,105 ordinary shares at a price of $17.30 per share, aiming to raise approximately $30 million in gross proceeds [1] - The offering is expected to close around September 30, 2025, pending customary closing conditions [1] - The net proceeds will primarily support EscharEx's pre-commercial activities, enhance manufacturing capabilities, and cover general corporate purposes [1] - H.C. Wainwright & Co. is the exclusive placement agent for this offering [1]